The market is sleeping on the job here. Pretty obvious that AZ has been in the pilot test phase which is why revenues haven't taken off. Once they properly start rolling out this market cap will look like a joke. I saw a similar thing happen with UBI and their Siemens partnered PT-INR product - an initial sales uptick followed by a lull (when the stock was sold down) and now some decent volumes building following a full marketing launch in the US.
Ann: Adherium receives US FDA 510k clearance, page-20
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ADR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.861M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 50256 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.12pm 04/10/2024 (20 minute delay) ? |
| ADR (ASX) Chart |
Day chart unavailable